5 Allergy Headlines You Missed in April 2026

April 2026 featured key updates in allergy, immunology, and rare disease, including FDA regulatory changes, phase 3 gene therapy results, and advances in prevention research. The FDA removed the age restriction for ARS Pharmaceuticals’ epinephrine nasal spray (neffy), shifting to weight-based pediatric use in younger patients. In hereditary angioedema (HAE), Intellia Therapeutics’ CRISPR-based lonvoguran ziclumeran (lonvo-z) delivered a large reduction in attack rates in the phase 3 HAELO trial.